Study analysis · Journal of Pharmacy Technology · 2022
This weekly shot helps people lose 15% of their body weight—here’s why it’s changing obesity treatment forever.
A weekly injection makes most people lose 15% of their weight just by helping them feel full longer and eat less.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This article doesn't do its own experiments — it just reads other studies and tells you what they found. So it can say 'other studies showed semaglutide helped people lose weight,' but it can't say 'semaglutide causes weight loss' on its own.
What’s the bottom line?
A medicine called semaglutide tricks the body into feeling full longer and slows down digestion, helping people eat less and lose weight when paired with diet and exercise.
How strong is this study?
This article is like a movie trailer — it shows cool clips from real movies (the RCTs), but it's not the movie itself. So it's helpful to get the highlights, but you can't trust it to prove anything unless you watch the real movies (the original trials).
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
13 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
31 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 52 / 100
Probability of being correct
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
This design cannot establish causation — the findings describe an association, not a cause. This is a narrative review, not an original study. It summarizes findings from other studies but does not conduct new experiments or randomization. Therefore, it cannot establish causation.
Key takeaways
- 01
People lost 15% of their body weight on average.
- 02
87 out of 100 people lost at least 5% of their weight.
- 03
Only 1 in 25 stopped because of side effects like nausea.
- 04
Losing 15% of body weight is a big deal—it can improve blood pressure, diabetes, and heart health.
Surprising findings
- The drug works better than liraglutide—by nearly 10% more weight loss.Liraglutide was the gold standard for GLP-1 weight loss drugs. Semaglutide isn’t just better—it’s dramatically better, making the previous top drug look outdated.
- Thyroid tumors were seen in rats—but never confirmed in humans.Despite a black box warning based on rodent data, no human cases of thyroid cancer have been linked to semaglutide in over 10,000 patient-years of exposure.
Practical takeaways
If you’re overweight with diabetes or high blood pressure, ask your doctor about semaglutide as an option—especially if diet/exercise alone hasn’t worked.
It’s expensive, requires weekly injections, and weight returns if you stop. It’s not a magic pill—it’s a tool that works best with lifestyle changes.
medium confidenceIf you’re considering stopping the drug, plan for weight regain—don’t assume you can 'maintain' the loss without it.
Long-term data only goes to 2 years. We don’t yet know if using it for 5+ years is safe or sustainable.
low confidenceWhy this study matters
15% Weight Loss? That’s Not a Myth
In the STEP trials reviewed, adults using semaglutide 2.4 mg lost an average of 14.9–16.0% of their body weight over 68 weeks—nearly 30 pounds for someone weighing 200 lbs. That’s more than double the weight loss seen with placebo (2.4–5.7%).
Losing 15% of your body weight isn’t just cosmetic—it can reverse type 2 diabetes, lower blood pressure, and reduce heart disease risk. Most weight loss drugs don’t come close.
9 Out of 10 People Succeed
87% of users achieved at least 5% weight loss—compared to only 31–48% with placebo or liraglutide. This makes semaglutide the most effective weight-loss drug ever tested in large trials.
Most weight loss programs fail 80% of people. This drug turns failure into success for the vast majority—changing the game for chronic obesity treatment.
Nausea Is Common—But Almost No One Quit
Up to 82% experienced nausea, vomiting, or diarrhea—but only 0.8–4.5% stopped taking it. Side effects usually faded within weeks, and most users kept going.
People assume side effects mean the drug doesn’t work. Here, the opposite is true: the side effects are the *sign* it’s working—and people tolerate them.
Stop the Shot, Gain It All Back
Weight loss is only maintained with continued use. Discontinuation leads to significant regain—meaning this isn’t a cure, but a lifelong treatment like insulin or blood pressure meds.
This shatters the 'quick fix' myth. People think weight loss drugs are temporary tools—but semaglutide is more like a daily vitamin for metabolism.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A medicine called semaglutide tricks the body into feeling full longer and slows down digestion, helping people eat less and lose weight when paired with diet and exercise.
Research results
People lost 15% of their body weight on average. 87 out of 100 people lost at least 5% of their weight. Only 1 in 25 stopped because of side effects like nausea.
What this means - more context
Losing 15% of body weight is a big deal—it can improve blood pressure, diabetes, and heart health.
To review the efficacy, safety, and role of once-weekly semaglutide 2.4 mg for chronic weight management in adults with obesity or overweight with comorbidities.
Semaglutide 2.4 mg, combined with lifestyle intervention, produces significant weight loss (14.9–16.0% over 68 weeks) superior to placebo (2.4–5.7%) and liraglutide 3.0 mg, with high responder rates (87% achieve ≥5% loss). Gastrointestinal side effects are common but rarely lead to discontinuation. Weight loss is maintained only with continued treatment; discontinuation causes significant regain. Contraindicated in patients with medullary thyroid carcinoma or MEN2 due to rodent thyroid tumor data.
Methods Used
Narrative review of English-language human studies identified via PubMed/MEDLINE, Google Scholar, and clinicaltrials.gov, focusing on phase 3 STEP trials of semaglutide 2.4 mg for weight management over up to 2 years.
Main Finding
Semaglutide 2.4 mg plus lifestyle intervention leads to 14.9–16.0% weight loss over 68 weeks, significantly greater than placebo (2.4–5.7%) and liraglutide (mean difference 9.4%), with 87% of patients achieving ≥5% weight loss.
Confidence Level
Moderate; based on synthesis of phase 3 RCTs (STEP trials) but the review itself is non-systematic and lacks statistical pooling or risk-of-bias assessment.
Study Flags
Red Flags
- •Narrative review without systematic methodology or meta-analysis
- •No original data or statistical pooling of effect sizes
- •Relies on external RCTs without assessing their individual risk of bias
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
The drug works better than liraglutide—by nearly 10% more weight loss.
Liraglutide was the gold standard for GLP-1 weight loss drugs. Semaglutide isn’t just better—it’s dramatically better, making the previous top drug look outdated.
Practical Takeaways
If you’re overweight with diabetes or high blood pressure, ask your doctor about semaglutide as an option—especially if diet/exercise alone hasn’t worked.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 52 / 100
Probability of being correct
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Narrative Review
Subject
Lower probability
on the GRADE evidence scale
This article doesn't do its own experiments — it just reads other studies and tells you what they found. So it can say 'other studies showed semaglutide helped people lose weight,' but it can't say 'semaglutide causes weight loss' on its own.
Strengths
- Comprehensive search of PubMed, Google Scholar, and ClinicalTrials.gov
- Includes multiple phase 3 RCTs from the STEP program
- Clearly distinguishes between semaglutide doses and populations
Weaknesses
- Narrative review — no systematic search strategy or quality assessment of included studies
- No meta-analysis or statistical pooling of data
- No assessment of publication bias
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A medicine called semaglutide tricks the body into feeling full longer and slows down digestion, helping people eat less and lose weight when paired with diet and exercise.
Research results
People lost 15% of their body weight on average. 87 out of 100 people lost at least 5% of their weight. Only 1 in 25 stopped because of side effects like nausea.
What this means - more context
Losing 15% of body weight is a big deal—it can improve blood pressure, diabetes, and heart health.
To review the efficacy, safety, and role of once-weekly semaglutide 2.4 mg for chronic weight management in adults with obesity or overweight with comorbidities.
Semaglutide 2.4 mg, combined with lifestyle intervention, produces significant weight loss (14.9–16.0% over 68 weeks) superior to placebo (2.4–5.7%) and liraglutide 3.0 mg, with high responder rates (87% achieve ≥5% loss). Gastrointestinal side effects are common but rarely lead to discontinuation. Weight loss is maintained only with continued treatment; discontinuation causes significant regain. Contraindicated in patients with medullary thyroid carcinoma or MEN2 due to rodent thyroid tumor data.
Methods Used
Narrative review of English-language human studies identified via PubMed/MEDLINE, Google Scholar, and clinicaltrials.gov, focusing on phase 3 STEP trials of semaglutide 2.4 mg for weight management over up to 2 years.
Main Finding
Semaglutide 2.4 mg plus lifestyle intervention leads to 14.9–16.0% weight loss over 68 weeks, significantly greater than placebo (2.4–5.7%) and liraglutide (mean difference 9.4%), with 87% of patients achieving ≥5% weight loss.
Confidence Level
Moderate; based on synthesis of phase 3 RCTs (STEP trials) but the review itself is non-systematic and lacks statistical pooling or risk-of-bias assessment.
Study Flags
Red Flags
- •Narrative review without systematic methodology or meta-analysis
- •No original data or statistical pooling of effect sizes
- •Relies on external RCTs without assessing their individual risk of bias
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
The drug works better than liraglutide—by nearly 10% more weight loss.
Liraglutide was the gold standard for GLP-1 weight loss drugs. Semaglutide isn’t just better—it’s dramatically better, making the previous top drug look outdated.
Practical Takeaways
If you’re overweight with diabetes or high blood pressure, ask your doctor about semaglutide as an option—especially if diet/exercise alone hasn’t worked.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 52 / 100
Probability of being correct
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Narrative Review
Subject
Lower probability
on the GRADE evidence scale
This article doesn't do its own experiments — it just reads other studies and tells you what they found. So it can say 'other studies showed semaglutide helped people lose weight,' but it can't say 'semaglutide causes weight loss' on its own.
Strengths
- Comprehensive search of PubMed, Google Scholar, and ClinicalTrials.gov
- Includes multiple phase 3 RCTs from the STEP program
- Clearly distinguishes between semaglutide doses and populations
Weaknesses
- Narrative review — no systematic search strategy or quality assessment of included studies
- No meta-analysis or statistical pooling of data
- No assessment of publication bias
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This article is like a movie trailer — it shows cool clips from real movies (the RCTs), but it's not the movie itself. So it's helpful to get the highlights, but you can't trust it to prove anything unless you watch the real movies (the original trials).
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
13 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
31 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 52 / 100
Probability of being correct
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
This design cannot establish causation — the findings describe an association, not a cause. This is a narrative review, not an original study. It summarizes findings from other studies but does not conduct new experiments or randomization. Therefore, it cannot establish causation.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
4 researchersIf this is your work, this is how we attribute it on Fit Body Science. Abby Fornes is listed as the lead author.